Akome’s AKO004 psychedelic drug formulation, for use in the treatment of Parkinson’s disease, is a composition comprising the psychedelic compound N,N-dimethyltryptamine (DMT) and, a specifically chosen, naturally occurring plant bioactive. Initial data analysis indicates that the AKO004 composition is safe and efficacious for use, and presents many positive properties which may counter or mitigate neurodegeneration including, anti-oxidant activity (through downregulation of adhesion molecules), oxidative stress suppression (through direct free radical scavenging), and upregulation of intracellular antioxidant defenses (e.g. enhancing glutathione levels). Additionally initial data mapping also suggests that the compound may play a neuroprotective role in the brain, generally. CLICK TO REVIEW